IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, N43DA-13-7

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$338,884.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
N43DA130037
Award Id:
n/a
Agency Tracking Number:
N43DA130037
Solicitation Year:
2013
Solicitation Topic Code:
NIDA
Solicitation Number:
n/a
Small Business Information
522 Second Avenue, REDWOOD CITY, CA, 94063-3848
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
160127655
Principal Investigator:
XINMIN XIE
(650) 784-5658
SIMONXIE@AFASCI.COM
Business Contact:
XINMIN XIE
(650) 784-5658
SIMONXIE@AFASCI.COM
Research Institution:
Stub




Abstract
Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profilefour FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated inObjective 1. PUBLIC HEALTH RELEVANCE

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government